MedPath

Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear

Not Applicable
Completed
Conditions
Myopia
Interventions
Device: fanfilcon A (test)
Device: enfilcon A (control)
Registration Number
NCT02555722
Lead Sponsor
Coopervision, Inc.
Brief Summary

This study is a masked, multi-center, daily wear, monthly replacement, bilateral, randomized, lens blocked (subjects remain in the same lens brand throughout the study) concurrent control study enrolling up to 90 subjects with a study duration of approximately three months. Subjects will be randomized into the study contact lenses in a two to one (2:1) ratio of fanfilcon A lens (test) to enfilcon A lens (control).

Detailed Description

Subjects will be randomized into the study contact lenses in a two to one (2:1) ratio of fanfilcon A lens (test) to enfilcon A lens (control). This should result in a study population of approximately 60 test subjects and 30 control subjects.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
92
Inclusion Criteria
  • Be at least 18 years of age as of the date of evaluation for the study.

  • Have:

    • Read the Informed Consent
    • Been given an explanation of the Informed Consent
    • Indicated understanding of the Informed Consent
    • Signed the Informed Consent document.
  • Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.

  • Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses at least 5 days per week for at least 8 hours per day for at least one month prior to participation in the study.

  • Possess or obtain prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.

  • Be in good general health, based on his/her knowledge.

  • Require spectacle lens powers between -0.50 and -8.00 diopters sphere with no more than 1.50 diopter of refractive astigmatism and be willing to wear contact lenses in both eyes.

  • Have manifest refraction Snellen visual acuities (VA) equal to or better than20/25 in each eye.

  • To be eligible for lens dispensing, the subject must achieve 20/30 VA or better in each eye with the study lens and the investigator must judge the fit as acceptable or optimal.

Exclusion Criteria
  • Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes for the duration of the study. Note: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.

  • Poor personal hygiene.

  • Any active participation in another clinical trial during this trial or within 30 days prior to this study.

  • To the best of the subject's knowledge, she is currently pregnant, is lactating or is planning a pregnancy within the next 3 months.

  • A member, relative or household member of the investigator or of the investigational office staff.

  • Has a known sensitivity to the ingredients used in the Multi-Purpose Disinfection Lens Care System (MPS) approved for use in the study and is unable or unwilling to use the alternate care system.

  • Previous refractive surgery; or current or previous orthokeratology treatment.

  • Is aphakic or pseudophakic.

  • Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, keratoconus or uncontrolled diabetes.

  • The need for topical ocular medications or any systemic medication which might interfere with contact lens wear or require the lenses to be removed during the day.

  • The presence of clinically significant (grade 2, 3 or 4) anterior segment abnormalities; or the presence of any inflammations such as iritis; or any infection of the eye, lids, or associated structures.

  • A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, iritis, bacterial or fungal infections.

  • A history of papillary conjunctivitis that has interfered with contact lens wear.

  • Slit lamp findings that would contraindicate contact lens wear, including but not limited to:

    • Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining > Grade 2
    • Pterygium
    • Corneal scars within the visual axis
    • Neovascularization or ghost vessels > 1.0 mm in from the limbus
    • Giant papillary conjunctivitis (GPC) of > Grade 2
    • Anterior uveitis or iritis
    • Seborrheic eczema, seborrheic conjunctivitis or blepharitis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
fanfilcon A (test)fanfilcon A (test)Subjects will be randomized to wear fanfilcon A lens (test) for one month of daily wear during the study.
enfilcon A (control)enfilcon A (control)Subjects will be randomized to wear enfilcon A lens (control) for one month of daily wear during the study.
Primary Outcome Measures
NameTimeMethod
Corneal Infiltrates - Enfilcon A Lens (Control)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Corneal infiltrates is assessed for enfilcon A lens (control). Grading scale: absent/present

Stromal Edema - Fanfilcon A Lens (Test)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Stromal edema is assessed for fanfilcon A lens (test). Grading Scale 0-4, 0=none, 1=trace, 2=mild, 3=moderate, 4=severe

Stromal Edema - Enfilcon A Lens (Control)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Stromal edema is assessed for enfilcon A lens (control). Grading Scale 0-4, 0=none, 1=trace, 2=mild, 3=moderate, 4=severe

Corneal Staining - Fanfilcon A Lens (Test)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Corneal staining with fluorescein is assessed for fanfilcon A lens (test). Grading Scale 0-4, 0=none, 1=trace, 2=mild, 3=moderate, 4=severe; Grading regions: S - Superior, T - Temporal, C - Central, N - Nasal, I - Inferior;

Epithelial Edema - Fanfilcon A Lens (Test)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Epithelial edema is assessed for fanfilcon A lens (test). Grading Scale 0-4, 0=none, 1=trace, 2=mild, 3=moderate, 4=severe

Palpebral Conjunctiva - Fanfilcon A Lens (Test)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Palpebral conjunctiva is assessed for fanfilcon A lens (test). Grading scale: Absent/present

Palpebral Conjunctiva - Enfilcon A Lens (Control)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Palpebral conjunctiva is assessed for enfilcon A lens (control). Grading scale: absent/present

Corneal Infiltrates - Fanfilcon A Lens (Test)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Corneal infiltrates is assessed for fanfilcon A lens (test). Grading scale: Absent/present

Corneal Vascularization - Fanfilcon A Lens (Test)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Corneal vascularization is assessed for fanfilcon A lens (test). Grading Scale 0-4, 0=none, 1=trace, 2=mild, 3=moderate, 4=severe

Limbal Hyperemia - Enfilcon A Lens (Control)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Limbal hyperemia is assessed for enfilcon A lens (control). Grading Scale 0-4, 0=none, 1=trace, 2=mild, 3=moderate, 4=severe

Bulbar Hyperemia - Fanfilcon A Lens (Test)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Bulbar hyperemia is assessed for fanfilcon A lens (test). Grading Scale 0-4, 0=none, 1=trace, 2=mild, 3=moderate, 4=severe

Bulbar Hyperemia - Enfilcon A Lens (Control)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Bulbar hyperemia is assessed for enfilcon A lens (control). Grading Scale 0-4, 0=none, 1=trace, 2=mild, 3=moderate, 4=severe

Visual Acuity - Fanfilcon A Lens (Test)Week 1, Week 2, Month 1, Month 2, Month 3

Visual acuity is assessed for fanfilcon A lens (test) using Snellen chart.

Visual Acuity - Enfilcon A Lens (Control)Week 1, Week 2, Month 1, Month 2, Month 3

Visual acuity is assessed for enfilcon A lens (control) using Snellen chart.

Average Wearing Time - Enfilcon A Lens (Control)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Average lens wearing time for enfilcon A lens (control) measured in hours.

Epithelial Edema - Enfilcon A Lens (Control)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Epithelial edema is assessed for enfilcon A lens (control). Grading scale 0-4, 0=none, 1=trace, 2=mild, 3=moderate, 4=severe

Limbal Hyperemia - Fanfilcon A Lens (Test)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Limbal hyperemia is assessed for fanfilcon A lens (test). Grading Scale 0-4, 0=none, 1=trace, 2=mild, 3=moderate, 4=severe

Corneal Vascularization - Enfilcon A Lens (Control)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Corneal vascularization is assessed for enfilcon A lens (control). Grading Scale 0-4, 0=none, 1=trace, 2=mild, 3=moderate, 4=severe

Corneal Staining - Enfilcon A Lens (Control)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Corneal staining with fluorescein is assessed for enfilcon A lens (control). Grading Scale 0-4, 0=none, 1=trace, 2=mild, 3=moderate, 4=severe; Grading regions: S - Superior, T - Temporal, C - Central, N - Nasal, I - Inferior;

Average Wearing Time - Fanfilcon A Lens (Test)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Average lens wearing time for fanfilcon A lens (test) measured in hours.

Secondary Outcome Measures
NameTimeMethod
Ease of Insertion and Removal - Fanfilcon A Lens (Test)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Ease of Insertion (EOI) and removal (EOR) was assessed. Subjects were asked to rate ease of insertion and removal on scale 0-5 (0=excellent, 1=very good, 2=good, 3=poor, 4=very poor, or 5=unmanageable.

Comfort - Fanfilcon A Lens (Test)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Fanfilcon A lens (test) are assessed regarding comfort for the following: comfort upon insertion (CUI), comfort during the day (CDD), end of the day comfort (EDC), overall comfort (OC), and comfort at visit (CV). Subjects were asked to rate comfort from 0-5 (0=excellent, 1=very comfortable, 2=comfortable, 3=slightly uncomfortable, 4=very uncomfortable, or 5=causes pain).

Comfort - Enfilcon A Lens (Control)Baseline, 1 week, 2 weeks, 1 month, 2 months, 3 months follow-up

Enfilcon A lens (control) are assessed regarding comfort for the following: comfort upon insertion (CUI), comfort during the day (CDD), end of the day comfort (EDC), overall comfort (OC), and comfort at visit (CV). Subjects were asked to rate comfort from 0-5 (0=excellent, 1=very comfortable, 2=comfortable, 3=slightly uncomfortable, 4=very uncomfortable, or 5=causes pain).

Ease of Insertion and Removal - Enfilcon A Lens (Control)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Ease of Insertion (EOI) and removal (EOR) was assessed. Subjects were asked to rate ease of insertion and removal on scale 0-5 (0=excellent, 1=very good, 2=good, 3=poor, 4=very poor, or 5=unmanageable.

Overall Vision Quality - Fanfilcon A Lens (Test)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Overall vision quality (OVQ) and vision at night (VAN) is assessed at the specific time points. Subjects were asked to rate vision from 0-5, (0=excellent, 1=very good, 2=good, 3=poor, 4=very poor, 5= unacceptable).

Overall Vision Quality - Enfilcon A Lens (Control)Baseline, Week 1, Week 2, Month 1, Month 2, Month 3

Overall vision quality (OVQ) and vision at night (VAN) is assessed at the specific time points. Subjects were asked to rate vision from 0-5, (0=excellent, 1=very good, 2=good, 3=poor, 4=very poor, 5= unacceptable).

Trial Locations

Locations (6)

Mark Nakano, O.D.

🇺🇸

Torrance, California, United States

Eric White, O.D., Inc.

🇺🇸

San Diego, California, United States

Advanced Family Eye Care

🇺🇸

Denver, North Carolina, United States

Primary Eyecare Group, P.C.

🇺🇸

Brentwood, Tennessee, United States

Western Reserve Vision Care, Inc.

🇺🇸

Beachwood, Ohio, United States

Quinn, Foster & Associates

🇺🇸

Athens, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath